Skip to main content

Advertisement

Log in

Post transplant lymphoproliferative disease: detection of tumor by Tc99m sestaMIBI and treatment with rituximab

  • Correspondence
  • Published:
Bone Marrow Transplantation Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Figure 1
Figure 2

References

  1. Baker KS, Defor TE, Burns LJ et al. New malignancies after blood or marrow stem cell transplantation in children and adults: incidence and risk factors. J Clin Oncol 2003; 21: 1352–1358.

    Article  Google Scholar 

  2. Marom EM, McAdams HP, Butnor KJ, Coleman RE . Positron emission tomography with fluoro-2-deoxy-D-glucose (FDG-PET) in the staging of post transplant lymphoproliferative disorder in lung transplant recipients. J Thorac Imaging 2004; 19: 74–78.

    Article  Google Scholar 

  3. Maurea S, Acampa W, Varella P et al. Tc-99m sestaMIBI imaging in the diagnostic assessment of patients with lymphomas: comparison with clinical and radiological evaluation. Clin Nucl Med 1998; 23: 283–290.

    Article  CAS  Google Scholar 

  4. Uno K, Kuyama J, Uchida Y et al. Tumor imaging in nuclear medicine. Nippon Rinsho 1996; 54: 1268–1272.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Paydas, S., Yapar, Z., Ergin, M. et al. Post transplant lymphoproliferative disease: detection of tumor by Tc99m sestaMIBI and treatment with rituximab. Bone Marrow Transplant 35, 317–318 (2005). https://doi.org/10.1038/sj.bmt.1704794

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704794

  • Springer Nature Limited

Navigation